McKesson (NYSE:MCK) updated its FY 2020
After-Hours earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 14.60-14.80 for the period, compared to the Thomson Reuters consensus estimate of $14.37. McKesson also updated its FY20 guidance to $14.60-14.80 EPS.
Shares of NYSE MCK traded up $0.31 during trading on Thursday, hitting $154.34. 1,647 shares of the company were exchanged, compared to its average volume of 955,153. The company has a fifty day moving average price of $141.13 and a 200-day moving average price of $141.59. The company has a debt-to-equity ratio of 1.36, a quick ratio of 0.57 and a current ratio of 1.01. The firm has a market capitalization of $27.15 billion, a PE ratio of 11.39, a P/E/G ratio of 1.46 and a beta of 1.12. McKesson has a 12-month low of $110.52 and a 12-month high of $155.93.
McKesson (NYSE:MCK) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $3.60 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $3.60. McKesson had a negative net margin of 0.29% and a positive return on equity of 32.77%. The business had revenue of $57.62 billion during the quarter, compared to the consensus estimate of $55.06 billion. During the same quarter last year, the firm earned $3.60 EPS. The business’s revenue was up 8.6% compared to the same quarter last year. Research analysts anticipate that McKesson will post 14.68 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 1.06%. The ex-dividend date of this dividend was Friday, November 29th. McKesson’s dividend payout ratio (DPR) is presently 12.09%.
MCK has been the subject of a number of research analyst reports. Morgan Stanley raised shares of McKesson from an equal weight rating to an overweight rating and increased their price objective for the stock from $135.00 to $162.00 in a research report on Friday, January 10th. TheStreet downgraded McKesson from a b rating to a c- rating in a research report on Wednesday, October 30th. UBS Group lowered shares of McKesson to a sell rating and set a $147.00 price objective for the company. in a research note on Thursday, January 9th. Finally, Mizuho increased their target price on shares of McKesson from $137.00 to $140.00 and gave the stock a neutral rating in a report on Wednesday. Three research analysts have rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $149.70.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
See Also: What is a Swap?
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.